banner news

Singapore, September 20, 2019 – Credo Diagnostics Biomedical Pte. Ltd., a groundbreaking point-of-care rapid molecular diagnostic company, will be featured in the newest episode of Advancements with Ted Danson that will broadcast Nationwide via CNBC on Saturday, September 21st @11:00am ET.


The segment will focus on Credo Diagnostics Biomedical’s new molecular diagnostic platform, VitaPCR. Combining speed, accuracy, and ease-of-use required for any advanced POC molecular diagnostic platform, VitaPCR Influenza A/B delivers rapid and actionable results for the same price level as RIDTs, making molecular diagnostic tools highly accessible to patients and affordable to all.


“Viewers will learn about Credo Diagnostics Biomedical's POC Real-Time PCR platform, which provides medical professionals with molecular diagnostic results at the point-of-care, to make critical decisions at a cost level traditionally reserved for rapid test.”


Advancements with Ted Danson will be aired on CNBC at 11:00am ET on Saturday, September 21st with multiple replays during the following weeks.


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.




We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.